Antiangiogenic and antiapoptotic treatment in advanced melanoma

Clinics in Dermatology

Volumn 31, Issue 3, 2013, Pages 257-263

  Nikolaou, Vasiliki ^a   Stratigos, Alexander ^a   Bafaloukos, Dimitrios ^b   Katsambas, Andreas ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b METROPOLITAN HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANGIOGENESIS INHIBITOR; AXITINIB; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CHIR 265; DACARBAZINE; DASATINIB; DOVITINIB; ERLOTINIB; EVEROLIMUS; FOTEMUSTINE; IPILIMUMAB; LACTATE DEHYDROGENASE; OBATOCLAX; PACLITAXEL; RAMUCRIMAB; SEPANTRONIUM BROMIDE; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VATALANIB; VEMURAFENIB;

ADVANCED CANCER; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER SURVIVAL; DRUG MEGADOSE; HUMAN; LOW DRUG DOSE; MELANOMA; METASTATIC MELANOMA; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN TARGETING; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CLINICAL TRIALS AS TOPIC; HUMANS; MELANOMA; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84876720112     PISSN: 0738081X     EISSN: 18791131     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2012.08.018     Document Type: Article

References (60)

1. Barth A., Wanek L.A., Morton D.L. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg 1995, 181:193-201.
2. Nikolaou V.A., Stratigos A.J., Flaherty K.T., Tsao H. Melanoma: new insight and new therapies. J Invest Dermatol 2012, 132:854-863.
3. Bafaloukos D.J., Linardou H. Targeting angiogenesis for the treatment of advanced melanoma. Oncology Rev 2011, 5:167-176.
4. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353-364.
5. Fidler I.J., Ellis L.M. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994, 79:185-188.
6. Simonetti O., Lucarini G., Brancorsini D., et al. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions. Cancer 2002, 95:1963-1970.
7. Potti A., Moazzam N., Tendulkar K., Javed N.A., Koch M., Kargas S. Immunohistochemical determination of vascular endothelial growth factor (VEGF) overexpression in malignant melanoma. Anticancer Res 2003, 23:4023-4026.
8. Rofstad E.K., Halsor E.F. Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts. Cancer Res 2000, 60:4932-4938.
9. Erhard H., Rietveld F.J., van Altena M.C., Brocker E.B., Ruiter D.J., de Waal R.M. Transition of horizontal to vertical growth phase melanoma is accompanied by induction of vascular endothelial growth factor expression and angiogenesis. Melanoma Res 1997, 7:S19-S26.
10. Ugurel S., Rappl G., Tilgen W., et al. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 2001, 19:577-583.
11. Mouawad R., Spano J.P., Comperat E., Capron F., Khayat D. Tumoural expression and circulating level of VEGFR-3 (Flt-4) in metastatic melanoma patients: correlation with clinical parameters and outcome. Eur J Cancer 2009, 45:1407-1414.
12. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285:1182-1186.
13. González-Cao M., Viteri S., Diaz-Lagares A., et al. Preliminary results of the combination of bevacizumab and weekly Paclitaxel in advanced melanoma. Oncology 2008, 74:12-16.
14. Perez D.G., Suman V.J., Fitch T.R., et al. Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A. Cancer 2009, 115:119-127.
15. Vihinen P.P., Hernberg M., Vuoristo M.S., et al. A phase II trial of bevacizumab with dacarbazine and daily low-dose interferonalpha2a as first line treatment in metastatic melanoma. Melanoma Res 2010, 20:318-325.
16. Von Moos R., Seifert B., Simcock M., et al. First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicenter phase II trial (SAKK 50/07). Ann Oncol 2012, 23:531-536.
17. Boasberg P., Cruickshank S., Hamid O., O'Day S., Weber R., Spitler L. Nab-paclitaxel and bevacizumab as first-line therapy in patients with unresectable stage III and IV melanoma. J Clin Oncol 2009, 27:15s.
18. Grignol V.P., Olencki T., Relekar K., et al. A phase 2 trial of bevacizumab and high-dose interferon alpha 2B in metastatic melanoma. J Immunother 2011, 34:509-515.
19. Del Vecchio M., Mortarini R., Canova S., et al. Bevacizumab plus fotemustine as first line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors. Clin Cancer Res 2010, 16:5862-5872.
20. Hainsworth J.D., Infante J.R., Spigel D.R., et al. Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: a phase 2 trial of the Sarah Cannon Oncology Research Consortium. Cancer 2010, 116:4122-4129.
21. Si L., Han M., Chi Z.H., et al. Durable response of the triple combination of temozolomide, sorafenib and bevacizumab to treat refractory stage IV acral melanoma. J Clin Oncol 2010, 28:15s.
22. Kim K.B., Sosman J.A., Fruehauf J.P., et al. BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol 2012, 30:34-41.
23. Peyton J.D., Spigel D.R., Burris H.A., et al. Phase II trial of bevacizumab and everolimus in the treatment of patients with metastatic melanoma: preliminary results. J Clin Oncol 2009, 27. abstr 9027.
24. Varker K.A., Biber J.E., Kefauver C., et al. A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol 2007, 14:2367-2376.
25. Wyman K., Spigel D., Puzanov I., et al. A multicenter phase II study of erlotinib and bevacizumab in patients with metastatic melanoma. J Clin Oncol 2007, 25. abstr 8539.
26. Desai N., Trieu V., Yao Z., et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of Cremophor-free, albumin-bound paclitaxel, ABI-007, compared with Cremophor-based paclitaxel. Clin Cancer Res 2006, 12:1317-1324.
27. Henderson I.C., Bhatia V. Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy. Expert Rev Anticancer Ther 2007, 7:919-943.
28. Hodi F.S., Friedlander P.A., Atkins M.B., et al. A phase I trial of ipilimumab plus bevacizumab in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2011, 29. abstr 8511.
29. Corrie P., Marshall A., East C., et al. Safety of adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence [abstract]. In 7th World Congress on Melanoma 2009, p237.
30. Spratlin J.L., Cohen R., Eadens M., et al. Phase 1 pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monocolonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 2010, 28:780-786.
31. Carvajal R.D., Wong M.K., Thompson J.A., et al. A phase II randomized study of ramucrimab (IMC-1121B) with or without dacarbazine (DTIC) in patients (pts) with metastatic melanoma (MM). J Clin Oncol 2010, 28:15s. (abstr 8519).
32. Eisen T., Ahmad T., Flaherty K.T., et al. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer 2006, 95:581-586.
33. Flaherty K.T., Schiller J., Schuchter L.M., et al. A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin Cancer Res 2008, 14:4836-4842.
34. Amaravadi R.K., Schuchter L.M., McDermott D.F., et al. Phase II trial of temozolomide and sorafenib in advanced melanoma patients with or without brain metastases. Clin Cancer Res 2009, 15:7711-7718.
35. Fruehauf J., Lutzky J., McDermott D., et al. Multicenter, phase II study of axitinib, a selective second generation inhibitor of vascular endothelial growth factor receptors 1,2, and 3, in patients with metastatic melanoma. Clin Cancer Res 2011, 17:7462-7469.
36. Kim K., Chesney J., Robinson D., Gardner H., Shi M., Kirkwood J. Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, n patients with advanced melanoma. Clin Cancer Res 2011, 17:7451-7461.
37. Cook N., Basu B., Kareclas P., et al. A phase 2 study of vatalanib in metastatic melanoma patients. Eur J Cancer 2010, 46:2671-2673.
38. Murukesh N., Dive C., Jayson G.C. Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer 2010, 102:8-18.
39. Soengas M.S., Lowe S.W. Apoptosis and melanoma chemoresistance. Oncogene 2003, 22:3138-3151.
40. Green D.R., Reed J.C. Mitochondria and apoptosis. Science 1998, 281:1309-1312.
41. Ashkenazi A., Dixit V.M. Death receptors: signaling and modulation. Science 1998, 281:1305-1308.
42. Galluzzi L., Larochette N., Zamzami N., Kroemer G. Mitochondria as therapeutic targets for cancer chemotherapy. Oncogene 2006, 25:4812-4830.
43. Soengas M.S., Capodieci P., Polsky D., et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001, 409:207-211.
44. Heere-Ress E., Thallinger C., Lucas T., et al. Bcl-X(L) is a chemoresistance factor in human melanoma cells that can be inhibited by antisense therapy. Int J Cancer 2002, 99:29-34.
45. Zhuang L., Lee C.S., Scolyer R.A., et al. Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. Mod Pathol 2007, 20:416-426.
46. Jansen B., Wacheck V., Heere-Ress E., et al. Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 2000, 356:1728-1733.
47. Bedikian A.Y., Millward M., Pehamberger H., et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006, 24:4738-4745.
48. Oltersdorf T., Elmore S.W., Shoemaker A.R., et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005, 435:677-681.
49. Konopleva M., Contractor R., Tsao T., et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT- 737 in acute myeloid leukemia. Cancer Cell 2006, 10:375-388.
50. Miller L.A., Goldstein N.B., Johannes W.U., et al. BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis. J Invest Dermatol 2009, 129:964-971.
51. Weber A., Kirejczyk Z., Potthoff S., Ploner C., Häcker G. Endogenous Noxa determines the strong proapoptotic synergism of the BH3-mimetic ABT-737 with chemotherapeutic agents in human melanoma cells. Transl Oncol 2009, 2:73-83.
52. Cragg M.S., Jansen E.S., Cook M., Harris C., Strasser A., Scott C.L. Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. J Clin Invest 2008, 118:3651-3659.
53. Keuling A.M., Andrew S.E., Tron V.A. Inhibition of p38 MAPK enhances ABT-737-induced cell death in melanoma cell lines: novel regulation of PUMA. Pigm Cell Mel Res 2010, 23:430-440.
54. Wang Y.F., Jiang C.C., Kiejda K.A., et al. Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1. Clin Cancer Res 2007, 13:4934-4942.
55. Mita A.C., Mita M.M., Nawrocki S.T., Giles F.J. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 2008, 14:5000-5005.
56. Altieri D.C. Survivin, cancer networks and pathway directed drug discovery. Nat Rev Cancer 2008, 8:61-70.
57. Grossman D., McNiff J.M., Li F. Expression and targeting of the apoptosis inhibitor, surviving, in human melanoma. J Invest Dermatol 1999, 113:1076-1081.
58. Nakahara T., Takeuchi M., Kinoyama I., et al. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 2007, 67:8014-8021.
59. Lewis K.D., Samlowski W., Ward J., et al. A multi center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma. Invest New Drugs 2011, 29:161-166.
60. Yamanaka K., Nakahara T., Yamauchi T., et al. Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models. Clin Cancer Res 2011, 17:5423-5431.